Marie Skłodowska-Curie Actions

It has been proven that AD biomarkers change decades before the development of symptoms. In addition, there is a lack of robust hypersensitive methods capable of predicting impending cognitive decline in healthy subjects at risk.

This constitutes a crucial obstacle for the implementation of AD prevention trials. To address this, we will identify and characterize a novel neurofeedback performance endophenotype in a subsample from a cohort of 2743 cognitively healthy volunteers at risk for AD.

This will be based on state-of-the-art neuroimaging technology, in combination with a novel sensitive neuropsychological test that detects subtle alterations in episodic memory, which has been validated for our cohort.